Entera Bio Ltd. (ENTX) fundamentals score
Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. Entera Bio concentrates on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 5.1 out of 10, Mixed fundamentals
- Growth: 5.8/10
- Profitability: 1.0/10
- Financial health: 7.7/10
- Earnings quality: 7.1/10
- Valuation: 5.2/10
Scores are calculated from Entera Bio Ltd.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10